According to Stifel GMP analyst Robert Fagan, the COVID-19 pandemic is actually a “net positive” for marijuana opereator Curaleaf Holdings Inc.

Amid the COVID-19 pandemic, sales of marijuana have increased for Curaleaf and shares of the company’s stock have gained 44% in the past five days.

In its earnings call late Tuesday, Curaleaf reported that the majority of its 54 stores are operational, avoiding delivery and offering on-premising filling of cannabis orders. The company highlighted about a 20% boost in sales.

Stifel GMP analyst Robert Fagan had suggested a 30% boost in growth as a result of the COVID-19 crisis would happen. The analyst has a C$22 target price on the stock.

“All in, we continue to believe cannabis is well-positioned versus other industries to outperform on a relative basis during unknowns on the coronavirus impact and believe Curaleaf is well-positioned given the company’s strong balance sheet and a majority of its revenues coming from markets that have deemed cannabis essential,” remarked Alliance Global Partners analyst Aaron Grey on Wednesday.

Grey rates Curaleaf a buy and lowered his target price to C$12 from C$14.

According to Canaccord Genuity analyst Matt Bottomley, the state shelter-in-place orders and other shutdown measures “could very possibly create moderate-to-high headwinds for the cannabis sector depending on the length/magnitude of these measures.”

Cowen analyst Vivien Azer wrote in a note to clients this week that her team was cautious about the company’s vape sales amid COVID-19, as “medical professionals are cautioning against vaping.” Azer rates Curaleaf the equivalent of a buy and has a $7 price target on U.S. shares.

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

D.C. Had A Lot of Arrests Last Year For Public Marijuana
12 July 2017
Researchers Find Genetic Differences Between Cannabis Strains
30 May 2019
Sacramento Just Had its First Legal Marijuana Fest in the Golden State
05 May 2018